THE FUSS is over a pill-an abortion pill that has been used safely for nearly a quarter-century, but has now become a political, medical, legal and regulatory hot potato. It's an intense legal battle with profound ramifications. Not only is it leading to more vociferous protests and campaigns in a society deeply divided on the matter, but it is undermining the very basis of regulation by an independent federal agency in the US.
The case that is roiling the US is a suit by a group of doctors who are seeking to curtail the availability of the nation's most used abortion drug, mifepristone. Approved in 2000 by the US Food and Drug Administration (FDA), its usage has increased steadily over the decades after it has proven to be safe and effective. According to the Guttmacher Institute, a non-governmental organisation that promotes reproductive rights worldwide, there were approximately 642,700 medication abortions in the US last year, accounting for 63 per cent of all abortions in the formal healthcare system. The numbers would be higher since the institute did not take into account the usage outside the formal system. In combination with misoprostol, the two-drug regimen is the most widely prescribed abortion therapy. As such, millions of women are anxious about the outcome of the doctors' lawsuit, as is FDA, since a hard right judiciary has passed orders that undercut its role in approving drugs and setting the rules for their usage.
The anti-abortion doctors and organisations in this suit claim participating in the care of women who have resorted to the use of the abortion pill "to end the life of the embryo or foetus would cause them emotional and moral harm". And how would this occur? They say there would be moral harm because patients who take abortion pills might seek treatment afterwards at emergency departments in hospitals where the doctors work.
Denne historien er fra April 16, 2024-utgaven av Down To Earth.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra April 16, 2024-utgaven av Down To Earth.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
Trade On Emissions
EU's Carbon Border Adjustment Mechanism, a tariff on imports, is designed to protect European industries in the guise of climate action.
'The project will facilitate physical and cultural decimation of indigenous people'
The Great Nicobar Project has all the hallmarks of a disaster-seismic, ecological, human. Why did it get the go-ahead?
TASTE IT RED
Popularity of Karnataka's red jackfruit shows how biodiversity can be conserved by ensuring that communities benefit from it
MANY MYTHS OF CHIPKO
Misconceptions about the Chipko movement have overshadowed its true objectives.
The politics and economics of mpox
Africa's mpox epidemic stems from delayed responses, neglect of its health risks and the stark vaccine apartheid
Emerging risks
Even as the world gets set to eliminate substances threatening the ozone layer, climate change and space advancement pose new challenges.
JOINING THE CARBON CLUB
India's carbon market will soon be a reality, but will it fulfil its aim of reducing emissions? A report by PARTH KUMAR and MANAS AGRAWAL
Turn a new leaf
Scientists join hands to predict climate future of India's tropical forests
Festering troubles
The Democratic Republic of Congo struggles to contain mpox amid vaccine delays, conflict and fragile healthcare.
India sees unusual monsoon patterns
THE 2024 southwest monsoon has, between June 1 and September 1, led to excess rainfall in western and southern states such as Gujarat, Maharashtra and Tamil Nadu, while others like Nagaland, Manipur and Punjab recorded a deficit.
